Peptide therapy timelines: what TikTok skips over

What did @elevii1 actually say?

The creator laid out a week-by-week timeline for a peptide they called "mati" — most likely a shorthand for a GH-releasing peptide combination or a similar compound. The claim: weeks one to two bring fatigue and no visible changes, week five delivers improved endurance and early body composition shifts, and weeks six to eight is when "people start to notice the most changes in the mirror." They capped it with a reasonable caveat: "these are just tools so all your other daily habits have to be dialed in."

That last line is genuinely good advice and deserves credit. The overall framing, though, treats a compound with limited peer-reviewed human data as if it has a well-established, predictable clinical timeline — and that's where the trouble starts.

Does the science back this up?

Mostly no, and the confidence of the timeline is the problem. The research base for peptide-driven body composition change in healthy adults is thin. Most human trials are small, short, and funded by parties with commercial interests.

For growth hormone secretagogues like ipamorelin or CJC-1295, studies do show increases in IGF-1 levels within weeks of administration. Sigalos and Pastuszak (2018, Current Urology Reports) reviewed GH secretagogues and found modest improvements in body composition over 8-12 weeks in clinical populations, not optimizing young adults at a gym. The fatigue claim in weeks one to two has almost no peer-reviewed support. That symptom could reflect nocturnal GH pulses disrupting sleep, but calling it a predictable adaptation phase is speculative. Nass et al. (2008, Annals of Internal Medicine) found that GH-axis manipulation in older adults improved lean mass but came with real side effects including fluid retention and insulin resistance, neither of which the creator mentioned.

What did they get wrong or right?

They got the general arc right: peptides that stimulate GH release do take weeks to produce measurable changes, and expecting results in days is unrealistic. The "biggest mistake people make is quitting far too early" is actually consistent with what the longer secretagogue trials show.

What they got wrong is the precision. Framing weeks five through eight as a near-universal checkpoint implies a clinical certainty that doesn't exist. Individual response varies enormously based on baseline GH status, diet, sleep quality, training age, and the specific compound and dose being used. The early fatigue framing is particularly problematic. Presenting a potential side effect as an expected, benign adaptation phase discourages users from reporting symptoms to a provider. That's a real clinical risk, not a minor quibble. The video also never once mentions any adverse effects beyond temporary workout fatigue, which paints an incomplete picture for a 50K-view audience.

What should you actually know?

If you're using a peptide through a regulated telehealth platform, your provider should be setting timeline expectations based on your bloodwork and health history, not a general TikTok chart. GH secretagogues work on a spectrum. Some people see IGF-1 changes in four weeks. Others see minimal shift after twelve. Neither outcome makes the video's specific weekly checkpoints accurate.

A few things the video skipped that matter:

• Peptide quality and source are enormous variables. Compounded peptides are not equivalent to research-grade compounds used in clinical trials.
• If you're experiencing persistent low energy beyond the first week or two, that warrants a conversation with your provider, not patience.
• Body composition changes visible "in the mirror" by week six to eight are almost certainly driven by the concurrent diet and exercise the creator mentioned, not the peptide alone. Disentangling those effects in a real-world setting is nearly impossible.

The video is well-intentioned and avoids making disease claims. But a timeline this specific, delivered this confidently, sets expectations that the current evidence base cannot support.